[1]Pluchino N, Santoro A, Casarosa E, et al. Advances in neurosteroids: role in clinical practice [J]. Climacteric, 2013, 16 (Suppl 1): 8-17.
[2]Schumacher M, Hussain R, Gago N, et al. Progesterone synthesis in the nervous system: implications for myelination and myelin repair [J]. Front Neurosci, 2012, 6:10.
[3]Wang QS, Qi ShSh, Zhou P, et al. Effects of allopregnanolone on the dopaminergic neurons in the substantia nigra of Alzheimer’s disease mice [J]. Acta Anatomica Sinica, 2013, 44 (2): 175-180 (in Chinese).
王琼仨, 戚双双, 周鹏, 等. 别孕烯醇酮对AD小鼠黑质多巴胺神经元的影响 [J]. 解剖学报, 2013, 44 (2): 175-180.
[4]Tagawa N, Katagiri M, Kobayashi Y. Developmental changes of serum steroids produced by cytochrome P450c17 in rat [J]. Steroids, 2006, 71(2): 165-170.
[5]Nguyen TV, McCracken JT, Ducharme S, et al. Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development [J]. J Neurosci, 2013, 33(26): 10840-10848.
[6]Miri A, Daie K, Burdine RD, et al. Regression-based identification of behavior-encoding neurons during large-scale optical imaging of neural activity at cellular resolution [J]. J Neurophysiol, 2011, 105(2): 964-980.
[7]Yoon SY, Roh DH, Seo HS, et al. An increase in spinal dehydroepiandrosterone sulfate (DHEAS) enhances NMDA-induced pain via phosphorylation of the NR1 subunit in mice: involvement of the sigma-1 receptor [J]. Neuropharmacology, 2010, 59(6): 460-467.
[8]Singh M, Su C. Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy [J]. Brain Res, 2013, 1514: 98-106.
[9]Meyer M, Gonzalez-Deniselle MC, Gargiulo-Monachelli G, et al. Progesterone effects on neuronal brain-derived neurotrophic factor and glial cells during progression of Wobbler mouse neurodeneration [J]. Neuroscience, 2012, 201: 267-279.
[10]Sitruk-Ware R, El-Etr M. Progesterone and related progestins: potential new health benefits [J]. Climacteric, 2013,16 (Suppl 1): 69-78.
[11]Labombarda F, Gonzalez-Deniselle MC, De Nicola AF, et al. Progesterone and the spinal cord: good friends in bad times [J]. Neuroimmunomodulation, 2010: 17(3):146-149.
[12]Schumacher M, Guennoun R, Robert F, et al. Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination [J]. Growth Horm IGF Res, 2004, 14 (Suppl A): S18-S33.
[13]Sameni H, Panahi M. The effect of co-administration of 4-methylcatechol and progesterone on sciatic nerve function and neurohistological alterations in streptozotocin-induced diabetic neuropathy in rats [J]. Cell J, 2011, 13(1): 31-38.
[14]Singh M, Su C. Progesterone, brain-derived neurotrophic factor and neuroprotection [J]. Neuroscience, 2013, 239: 84-91.
[15]Yang N, Zuchero JB, Ahlenius H, et al. Generation of oligodendroglial cells by direct lineage conversion [J]. Nat Biotechnol, 2013, 31(5): 434-439.
[16]Azizi H, Mehrjardi NZ, Shahbazi E, et al. Dehydroepiandrosterone stimulates neurogenesis in mouse embryonal carcinoma cell- and human embryonic stem cell-derived neural progenitors and induces dopaminergic neurons [J]. Stem Cells Dev, 2010, 19(6): 809-818.
[17]Moriguchi S, Shinoda Y, Yamamoto Y, et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice [J]. PLoS One, 2013,8(4): e60863.
[18]Jacob MH, Janner Dda R, Araújo AS, et al. Redox imbalance influence in the myocardial Akt activation in aged rats treated with DHEA [J]. Exp Gerontol, 2010, 45(12): 957-963.
[19]Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications [J]. Nat Rev Endocrinol, 2013, 9(4): 241-250.
[20]Sun C, Ou X, Farley JM, et al. Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer’s disease [J]. Curr Alzheimer Res, 2012, 9(4): 473-480.
[21]Irwin RW, Wang JM, Chen S, et al. Neuroregenerative mechanisms of allopregnanolone in Alzheimer’s disease [J]. Front Endocrinol (Lausanne), 2012, 2: 117.
[22]Evans J, Sun Y, McGregor A, et al. Allopregnanolone regulates neurogenesis and depressive /anxiety-like behaviour in a social isolation rodent model of chronic stress [J]. Neuropharmacology, 2012, 63(8): 1315-1326.
[23]Wakabayashi K. Cellular pathology of neurodegenerative disorders [J]. Rinsho Shinkeigaku, 2013, 53(8): 609-617. (in Japanese)
[24]Nakamura T, Cho DH, Lipton SA. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases [J]. Exp Neurol, 2012, 238(1): 12-21.
[25]Viana RJ, Fonseca MB, Ramalho RM, et al. Organelle stress sensors and cell death mechanisms in neurodegenerative diseases [J]. CNS Neurol Disord Drug Targets, 2010, 9(6): 679-692.
[26]Itoh T, Imano M, Nishida S, et al. Increased apoptotic neuronal cell death and cognitive impairment at early phase after traumatic brain injury in aged rats [J]. Brain Struct Funct, 2013, 218(1): 209-220.
[27]Sarkar J, Wakefield S, MacKenzie G, et al. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors [J]. J Neurosci, 2011, 31(50): 18198-18210.
[28]Perzylo K, Kulik-Rechberger B, Galczynski K, et al. Intracrinology and dehydroepiandrosterone—a new perspective for the use of androgens in hormonereplacement therapy in postmenopausal women [J]. Ginekol Pol, 2011, 82(9): 690-695. (in Polish)
[29]Lopes JP, Tarozzo G, Reggiani A, et al. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity [J]. Brain Behav, 2013, 3(2): 67-74.
[30]Balasuriya D, Goetze TA, Barrera NP, et al. α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors adopt different subunit arrangements [J]. J Biol Chem, 2013, 288(30): 21987-21998.
[31]Wang M. Neurosteroids and GABA-a receptor function [J]. Front Endocrinol (Lausanne), 2011, 2: 44.
[32]Smith SS, Aoki C, Shen H. Puberty, steroids and GABA(A) receptor plasticity [J]. Psychoneuroendocrinology, 2009, 34 (Suppl 1): S91-S103.
[33]Gartside SE, Griffith NC, Kaura V, et al. The neurosteroid dehydroepiandrosterone (DHEA) and its metabolites alter 5-HT neuronal activity via modulation of GABAA receptors [J]. J Psychopharmacol, 2010, 24(11): 1717-1724.
[34]Nakano M, Osada K, Misonoo A, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells [J]. Life Sci, 2010, 89(9-10), 309-314.
[35]Yao J, Chen S, Cadenas E, et al. Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons [J]. Brain Res, 2011, 1379: 2-10.
[36]Vaudry H, Tsutsui K. Research topic: neurosteroids [J]. Front Endocrinol (Lausanne), 2012, 3: 126.
[37]Bracamontes J, McCollum M, Esch C, et al. Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABAA receptor induced from either transmitter binding site [J]. Mol Phamacol, 2011, 80(1): 79-86.
[38]Maril S, Hassin-Baer S, Cohen OS, et al. Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson’s disease [J]. Neuropsychologia, 2013, 51(5): 818-824.
[39]Rustichelli C, Pinetti D, Lucchi C, et al. Simultaneous determination of pregnenolone sulphate, dehydroepiandrosterone and allopregnanolone in rat brain areas by liquid chromatography-electro-spray tandem mass spectrometry [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 930: 62-69.
[40]Gonzalez-Castaneda RE, Galvez-Contreras AY, Luquín S, et al. Neurogenesis in Alzheimer’s: a realistic alternative to neuronal degeneration [J]? Curr Signal Transduct Ther, 2011, 6(3): 314-319.
[41]Yang R, Chen L, Wang H, et al. Anti-amnesic effect of neurosteroid PREGS in Aβ25-35-injected mice throughσ1 receptor-and α7nAChR-mediated neuroprotection [J]. Neuropharmacology, 2012, 63(6): 1042-1050.
[42]Lopez ME, Klein AD, Scott MP. Complement is dispensable for neurodegeneration in Niemann-Pick disease type C [J]. J Neuroinflammation, 2012, 9: 216. |